Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Investment
Vertex and Lonza team on type 1 diabetes
by Rick Mullin
June 30, 2023
| A version of this story appeared in
Volume 101, Issue 21
Vertex Pharmaceuticals and Lonza, the Swiss pharmaceutical services firm, have entered a agreement to manufacture Vertex’s investigational islet cell therapies for treatment of type 1 diabetes; the therapies are derived from stem cells and are insulin producing. The effort is currently focused on the candidates VX-880 and VX-264, which are in clinical trials. The partners are building a dedicated manufacturing facility at Lonza’s Portsmouth, New Hampshire, site. The new facility will employ 300 people.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter